SCHEMBL4026176

SCHEMBL4026176

Cc1c(F)cccc1C1[C@@H](C(=O)c2nccs2)CN(C)C[C@@H]1C(=O)c1nccs1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.39
MEN1 O00255 2/20 0.39
MGLL Q99685 4/20 0.37
CYP2D6 P10635 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C19 P33261 1/20 0.36
CASP3 P42574 1/20 0.36
SENP8 Q96LD8 1/20 0.36
SENP7 Q9BQF6 1/20 0.36
SENP6 Q9GZR1 1/20 0.36
RBP4 P02753 1/20 0.36
TAAR1 Q96RJ0 1/20 0.36
MAPK1 P28482 1/20 0.36
KDM4E B2RXH2 1/20 0.36
CD274 Q9NZQ7 1/20 0.36
HCRTR1 O43613 1/20 0.36
HCRTR2 O43614 1/20 0.36
ALDH1A1 P00352 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4021793 0.86 KDM4E (0.39) KMT2AMGLLCYP2D6CYP1A2CYP2C19
SCHEMBL4021790 0.86 KDM4E (0.39) KMT2AMGLLCYP2D6CYP1A2CYP2C19
SCHEMBL4020952 0.85 EED (0.37) KMT2AMGLLCYP2D6CYP1A2CYP2C19
SCHEMBL4020948 0.85 EED (0.37) KMT2AMGLLCYP2D6CYP1A2CYP2C19
SCHEMBL4023704 0.84 KMT2A (0.37) KMT2AMEN1MGLLCYP2D6CYP1A2
SCHEMBL4023706 0.84 KMT2A (0.37) KMT2AMEN1MGLLCYP2D6CYP1A2
SCHEMBL4752708 0.84 MEN1 (0.43) KMT2AMEN1CYP2D6TAAR1MAPK1
SCHEMBL4749201 0.77 MEN1 (0.44) KMT2AMEN1CYP2D6TAAR1MAPK1
SCHEMBL4748993 0.77 MEN1 (0.44) KMT2AMEN1CYP2D6TAAR1MAPK1
SCHEMBL4024616 0.77 KMT2A (0.32) KMT2ACD274

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7572814-B2 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds CYTOKINETICS, INCORPORATED (US) 2009-08-11 US disclosed
EP-1962846-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-09-03 EP disclosed
US-20070161674-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. 2007-07-12 US disclosed
WO-2007059323-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161674-A1 Certain chemical entities, compositions, and methods TP53, VHL, RB1 KMT2A 2820/4885MEN1 77/4885MGLL 2929/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.